Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 31755336)

  • 1. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
    Rathi E; Kumar A; Kini SG
    J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
    Bhojwani HR; Joshi UJ
    Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer.
    Mohan A; Krishnamoorthy S; Sabanayagam R; Schwenk G; Feng E; Ji HF; Muthusami S
    Eur J Pharmacol; 2023 Oct; 957():175961. PubMed ID: 37549730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
    Konidala KK; Bommu UD; Pabbaraju N
    J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Four New Chemical Series of Small Drug-Like Natural Products as Potential Neuropilin-1 Inhibitors by Structure-Based Virtual Screening: Pharmacophore-Based Molecular Docking and Dynamics Simulation.
    Sabki A; Khelifi L; Kameli A; Baali S
    Chem Biodivers; 2023 Mar; 20(3):e202200933. PubMed ID: 36799050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel VEGFR2-TK inhibitors by phthalimide pharmacophore based virtual screening, molecular docking, MD simulation and DFT.
    Matore BW; Roy PP; Singh J
    J Biomol Struct Dyn; 2023; 41(22):13056-13077. PubMed ID: 36775656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of octahydropyrrolo [3,2-b] pyridin derivative as a highly selective Type I inhibitor of FGFR3 over VEGFR2 by high-throughput virtual screening.
    Wang X; Ye CH; Li EM; Xu LY; Lin WQ; Chen GH
    J Cell Biochem; 2023 Feb; 124(2):221-238. PubMed ID: 36502529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of potentially high drug-like VEGFR2/c-Met dual-target type II kinase inhibitors with symmetric skeletons based on structural screening.
    Xie J; Zhang X; Meng D; Li Y; Deng P
    J Biomol Struct Dyn; 2024; 42(3):1249-1267. PubMed ID: 37042992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors.
    Hoi PM; Li S; Vong CT; Tseng HH; Kwan YW; Lee SM
    Methods; 2015 Jan; 71():85-91. PubMed ID: 25239735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based identification of potent VEGFR-2 inhibitors from in vivo metabolites of a herbal ingredient.
    Dash R; Junaid M; Mitra S; Arifuzzaman M; Hosen SMZ
    J Mol Model; 2019 Mar; 25(4):98. PubMed ID: 30904971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
    Iqbal S; Anantha Krishnan D; Gunasekaran K
    J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational Investigation Identified Potential Chemical Scaffolds for Heparanase as Anticancer Therapeutics.
    Parate S; Kumar V; Danishuddin ; Hong JC; Lee KW
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34156395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.
    Rampogu S; Baek A; Zeb A; Lee KW
    BMC Cancer; 2018 Mar; 18(1):264. PubMed ID: 29514608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
    Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
    Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
    Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
    J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Novel EGFR Inhibitors for the Targeted Therapy of Colorectal Cancer Using Pharmacophore Modelling, Docking, Molecular Dynamic Simulation and Biological Activity Prediction.
    Krishnan K A; Valavi SG; Joy A
    Anticancer Agents Med Chem; 2024; 24(4):263-279. PubMed ID: 38173208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors.
    Rajagopalan M; Balasubramanian S; Ramaswamy A; Mathur PP
    J Enzyme Inhib Med Chem; 2013 Dec; 28(6):1236-46. PubMed ID: 23061928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.